Clinical trials for lupus nephritis lacking
More long-term randomized controlled trials on therapies for the treatment of lupus nephritis (LN) are needed, especially those that focus on membranous LN, childhood-onset LN, and maintenance phase LN, as the majority of current trials focus on adult proliferative LN, according to a study.
Of the 126 eligible therapeutic trials registered on ClinicalTrials.gov up to December 3, 2020, half enrolled <50 participants, and the majority (70.7%) had a duration of 6-24 months. Treatment of adult proliferative LN was mainly investigated
Overall, 95.2% of trials were interventional, with 56.6% in phase 2 or phase 3, 76.7% randomized, 77.5% employing a parallel assignment, and 41.7% masked.
There were no standardized eligibility criteria and outcome measures.
The most studied immunotherapies were chemical agents and biologics; mycophenolate mofetil, tacrolimus, and rituximab were the most studied
The authors note that some trials studied cell transplantation treatment.
Gao Y, Wang Y, Li R, et al. Comprehensive analysis of clinical trials registration for lupus nephritis therapy on ClinicalTrials.gov. Front Med (Lausanne). 2021;8:680302. doi: 10.3389/fmed.2021.680302. PMID: 34222288; PMCID: PMC8248800.